100 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
6 Jun 24
Submission of Matters to a Vote of Security Holders
4:29pm
, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
to close on or about May 7, 2024, subject to market conditions and the satisfaction of customary closing conditions.
Piper Sandler, Guggenheim … and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending … with to the Representatives’ reasonable satisfaction; and all necessary regulatory or stock exchange approvals shall have been received.
(b) (i) At the Closing Date
8-K
EX-10.1
d1dpvht63dyyl
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
S-3ASR
EX-4.3
emfs67b
2 Jan 24
Automatic shelf registration
4:06pm
8-K
4ltwmhdk jr
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
0wh bw7yiovkyxjzkpnx
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-99.1
hx35ce
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
2bfjjzt9mb3o
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
h2onvbd9 wonz
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
8h5losxmhoubr
29 Sep 23
Prospectus supplement for primary offering
4:51pm
S-3MEF
EX-5.1
z4nic5 kt
27 Sep 23
Registration of additional securities for an S-3
9:32pm
424B5
ui7ehro90 qj4g
27 Sep 23
Prospectus supplement for primary offering
5:26pm